~~<i id='155200C1FB'><strike id='155200C1FB'><tt id='155200C1FB'><pre id='155200C1FB'></pre></tt></strike></i>~~

Home» explore» hotspot

hotspot

author：hotspot 2025-09-28 13:05:44 Page View：317

Damian Garde of STAT talks with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho at STAT in NYC. — Damian Garde of STAT, left, talked with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho about the GLP-1 weight loss market. Michelle C. Gevint for STAT

NEW YORK — Will the world actually soon spend $100 billion a year on the new obesity medicines?

Plenty of people in pharma and at the banks that invest in it seem to think so. Goldman Sachs, Barclays, BMO Capital Markets and Pfizer have all arrived at the glossy, cut-for-headline number for spending by around 2030.

Yet Jared Holz, a healthcare strategist at Mizuho, is skeptical.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Novo acquires Inversago for up to $1 billion
Next article： Duchenne breakthrough therapy leaves behind pioneering families

explore

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

6:16PresidentJoeBidenspeaksintheRooseveltRoomoftheWhiteHouse,June30,2023.EvanVucci/APPresidentJoeBid

The Readout: Abbvie and Humira, CRISPR in utero, Annovis Bio

RubyWallauforSTATWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechne

23andMe had bad news about my health. I wish a person had delivered it

ERICBARADAT/AFP/GettyImagesLastsummer,IthoughtitmightbefuntohavemyDNAanalyzed.Twocompanies,23andMean

Antivenom research: Lessons from HIV applied in search for universal antidote

MarkRalston/AFP/GettyImagesAntivenom,likeMexicanCokeorgrandma’scookies,isstillmadetheold-fashionedwa

WSS

hotspot

hotspot

leisure time

explore

Antivenom research: Lessons from HIV applied in search for universal antidote